Poland – 2025/02/22: In this photography imaging, the Biotech Logo is displayed … more
“In the 30 years of my oncology, we didn’t talk about myeloma treatment.” These are the words of the University of North Carolina Professor of Cancer Policy, Norman Sharpless, referenced to New York Times. For those who do not know, multiple myeloma is a blood cancer that is well known as incurable.
That poses a question: What will readers do if they received a multiple myeloma diagnosis? It is no scope to say that most of us would ask the doctor to relay the horrible news if there is any hope, any treatment or any possible treatment anywhere. This will be especially true with myeloma, since the traditional course toward death within a time of diagnosis is described by the Times as “extremely painful”.
Enter Legend Biotech, a Somerset, NJ Biotechnology Company. THE Times It says that immunotherapy was developed where it began as a “Last Handy” option five years ago for about 100 patients with myeloma. The encouraging, beautiful news is that a third emerged from what was traditionally a death penalty and without cancer.
To say that what is happening in Legend Biotech is an exciting developmental offensive. Finally, after this time there is progress. And progress exists as optimism that we are on the doorstep of many more remarkable jumps. That requires another pause.
Although the myth is based in Somerset, NJ, its origin is Chinese. Does it ask a question: Would death readers deny the treatments developed by the myth or some other pharmaceutical company operating in China? One assumes that the question answers himself. In issues of life and death, there is a natural tendency to do what they need to survive, especially if they have children.
It is just a comment that when death looks at our face, no pause is required. We are wired to look great for what will keep us upright.
The main thing is that while Legend is now New Jersey, he still has businesses in China. Good. The more people are financially integrated, the better we are all. In other words, it is not a threat of “national security” when the big jumps of AI, economic or pharmaceutical variety hatch somewhere not the United States.
Format that if the trading strips are open, it is as if all the largest products, services and treatments in the world are created. And when market goods cross the borders regardless of the origin of the country, the war of shooting and bombing becomes terribly expensive.
Looking at taxes, LEGEND’s global footprint is hopeful that a reminder to US tax writers that when it comes to innovative developments intended to cure some of the worst diseases, it is extremely wrong to be taxed “made in America”. The more American pharmaceutical companies benefit from world talent, the better the US drugs will be. And the more tax policy is neutral as it is applied to US companies, the easier they will be able to get the best of the best in the world.
The simple and ultimately salvation is that productivity is a result of cooperation in so many hands, machines and engines that think as possible. Drugs are not unique in this respect. The most specialized collaboration on the development of moon style treatments, both faster in the treatment.
Sharpless continued to say the Times That “this is the first time we have been really serious about treatments in one of the worst malignancies we can imagine.” The brilliant fruits of swinging talents on the opposite sides of the world.
It’s something you have to remember. Closed, though it may sound, there is no limit to progress when combining specialized genius. Let us not allow tax writers to create obstacles in this collaboration exclusively because genius occasionally has a foreign address.
